Clarivate (NYSE:CLVT – Get Free Report) will release its earnings data before the market opens on Wednesday, November 6th. Analysts expect Clarivate to post earnings of $0.16 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Clarivate (NYSE:CLVT – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. The company had revenue of $650.30 million during the quarter, compared to the consensus estimate of $651.94 million. Clarivate had a positive return on equity of 10.01% and a negative net margin of 46.53%. Clarivate’s revenue was down 2.8% on a year-over-year basis. During the same period last year, the company earned $0.16 earnings per share. On average, analysts expect Clarivate to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Clarivate Stock Performance
Shares of NYSE:CLVT opened at $6.45 on Tuesday. The company has a current ratio of 0.90, a quick ratio of 0.90 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $4.67 billion, a price-to-earnings ratio of -3.38 and a beta of 1.18. Clarivate has a 12 month low of $4.97 and a 12 month high of $9.60. The firm’s 50-day moving average is $6.68 and its 200 day moving average is $6.32.
Analyst Ratings Changes
Get Our Latest Analysis on Clarivate
Insider Buying and Selling at Clarivate
In other news, insider Bar Veinstein sold 120,000 shares of the firm’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $7.00, for a total transaction of $840,000.00. Following the completion of the transaction, the insider now directly owns 976,583 shares in the company, valued at $6,836,081. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Bar Veinstein sold 120,000 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $7.00, for a total transaction of $840,000.00. Following the sale, the insider now directly owns 976,583 shares of the company’s stock, valued at $6,836,081. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Saurabh Saha sold 17,646 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $6.75, for a total transaction of $119,110.50. Following the sale, the director now owns 23,741 shares in the company, valued at approximately $160,251.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 197,646 shares of company stock valued at $1,379,111 over the last 90 days. 22.77% of the stock is owned by insiders.
Clarivate Company Profile
Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers Web of Science and InCites, that analyzes and explores the academic research landscape and manages research information; ProQuest One and Ebook Central that provides comprehensive content collections to institutions in a cost-effective manner; and Alma and Polaris, that manages academic resources and services, connect users, and support research publications.
Further Reading
- Five stocks we like better than Clarivate
- How to Invest in Insurance Companies: A Guide
- Intel: Is Now the Time to Be Brave?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How to Effectively Use the MarketBeat Ratings Screener
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.